Advertisement

Hypertension and Hypertrophic Cardiomyopathy

  • Andrew WangEmail author
Chapter

Abstract

Across the age spectrum of HCM, HTN is a common, comorbid condition in approximately half of all HCM patients. HCM and hypertensive cardiomyopathy lead to similar structural abnormalities in the myocardium, but these are generally more pronounced in HCM. A composite of clinical variables may be used to differentiate these conditions. The appropriate treatment of HTN in HCM is not well defined, and recommendations for use of drugs with blood pressure-lowering effects have focused largely on the potential for exacerbating left ventricular outflow obstruction by reducing preload or afterload, rather than clinical endpoints used in outcome studies of HTN treatments.

Keywords

Hypertrophy Hypertension Treatment Cardiomyopathy 

References

  1. 1.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076–80.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after Septal Myectomy and alcohol Septal ablation for treatment of obstructive hypertrophic Cardiomyopathy: US Nationwide inpatient database, 2003-2011. JAMA Cardiol. 2016;1(3):324–32.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Cannan CR, Reeder GS, Bailey KR, Melton LJ 3rd, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation. 1995;92(9):2488–95.CrossRefGoogle Scholar
  5. 5.
    Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2017;103(9):672–8.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Savage DD, Drayer JI, Henry WL, Mathews EC Jr, Ware JH, Gardin JM, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation. 1979;59(4):623–32.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327–34.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19(7):1550–8.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension. 1997;29(1 Pt 1):22–9.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26(7):1699–708.CrossRefGoogle Scholar
  11. 11.
    Sheikh N, Papadakis M, Panoulas VF, Prakash K, Millar L, Adami P, et al. Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. Heart. 2016;11:7–11.Google Scholar
  12. 12.
    Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81(4):459–67.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53(3):284–91.CrossRefGoogle Scholar
  14. 14.
    Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95.CrossRefGoogle Scholar
  15. 15.
    Wu LM, An DL, Yao QY, Ou YZ, Lu Q, Jiang M, et al. Hypertrophic cardiomyopathy and left ventricular hypertrophy in hypertensive heart disease with mildly reduced or preserved ejection fraction: insight from altered mechanics and native T1 mapping. Clin Radiol. 2017;72:835.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60.CrossRefGoogle Scholar
  17. 17.
    Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(7):1016–22.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Kato TS, Noda A, Izawa H, Yamada A, Obata K, Nagata K, et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation. 2004;110(25):3808–14.CrossRefGoogle Scholar
  19. 19.
    Dimitrow PP, Czarnecka D, Kawecka-Jaszcz K, Dubiel JS. The frequency and functional impact of hypertension overlapping on hypertrophic cardiomyopathy: comparison between older and younger patients. J Hum Hypertens. 1998;12(9):633–4.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C. Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Force m A/T, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.CrossRefGoogle Scholar
  24. 24.
    Betocchi S, Piscione F, Losi MA, Pace L, Boccalatte M, Perrone-Filardi P, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol. 1996;78(4):451–7.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123–31.CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109(10):1284–91.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of Aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376–85.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Chan WL, Gilligan DM, Ang EL, Oakley CM. Effect of preload change on resting and exercise cardiac performance in hypertrophic cardiomyopathy. Am J Cardiol. 1990;66(7):746–51.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Cardiovascular Disease Fellowship ProgramDurhamUSA

Personalised recommendations